Novo Nordisk CEO Lars Fruergaard Jørgensen. Novo Nordisk CEO Lars Fruergaard Jørgensen stated Friday that the business’s speculative weight reduction tabletAmycretin, “might turn into a best-in-class medication.” His discuss CNBC….
Novo Nordisk’s sales in 2023 jumped 31% year-over-year to 232.3 billion Danish kroner ($33.8 billion).Image: Staff (Reuters) A new class of weight loss drugs hasn’t simply expanded the profits of….
Another week, another research study finding that Ozempic/Wegovy and comparable drugs might do a lot more than simply assist individuals drop weight. New research study has actually discovered that clients….
Novo Nordisk A/S, the Danish manufacturer of blockbuster obesity drugs Ozempic and Wegovy, is planning a “mega manufacturing facility” outside of Dublin in a bid to keep up with soaring….
Endocrinology > Type 2 Diabetes — Agency seized thousands of counterfeit units already by Kristen Monaco, Senior Staff Writer, MedPage Today December 22, 2023 The FDA continues its investigation into….